[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last week. The study highlights, including a favorable safety profile and potential efficacy in disease control, likely garnered positive investor sentiment. Nevertheless, the company's stock movement is congruent with broader market trends, as the market climbed 1.7% over the same period, likely...",
    "url": "https://finnhub.io/api/news?id=d59436fdb5b748408129dff6b114f16279c1b9c0f1dd375f6cfa24f72ed9d25d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748884801,
      "headline": "Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig",
      "id": 134952905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last week. The study highlights, including a favorable safety profile and potential efficacy in disease control, likely garnered positive investor sentiment. Nevertheless, the company's stock movement is congruent with broader market trends, as the market climbed 1.7% over the same period, likely...",
      "url": "https://finnhub.io/api/news?id=d59436fdb5b748408129dff6b114f16279c1b9c0f1dd375f6cfa24f72ed9d25d"
    }
  },
  {
    "ts": null,
    "headline": "June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035",
    "summary": "Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and smart diversification...",
    "url": "https://finnhub.io/api/news?id=1a1690d0d6fa893c1191db6a53ce4c2ce65038e5023a9acbfc5ebed5211df28f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748880000,
      "headline": "June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035",
      "id": 134959783,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156964801/image_2156964801.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and smart diversification...",
      "url": "https://finnhub.io/api/news?id=1a1690d0d6fa893c1191db6a53ce4c2ce65038e5023a9acbfc5ebed5211df28f"
    }
  },
  {
    "ts": null,
    "headline": "ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug",
    "summary": "The trial enrolled 174 subjects aged 36–89 years who had undergone an average of four previous therapies.",
    "url": "https://finnhub.io/api/news?id=540a5afccd313fae55ec21ddf5babf390939c774597cb3d508d5935698c53d87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748875326,
      "headline": "ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug",
      "id": 134952908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The trial enrolled 174 subjects aged 36–89 years who had undergone an average of four previous therapies.",
      "url": "https://finnhub.io/api/news?id=540a5afccd313fae55ec21ddf5babf390939c774597cb3d508d5935698c53d87"
    }
  },
  {
    "ts": null,
    "headline": "Lord Abbett Developing Growth Fund Q1 2025 Commentary",
    "summary": "The Fund returned -17.65%, reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended March 31, 2025.",
    "url": "https://finnhub.io/api/news?id=a63404a629040b3ee1dfbeb821589ec1ac714a5cd7b1b3f88d08123c42a9a6a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748868780,
      "headline": "Lord Abbett Developing Growth Fund Q1 2025 Commentary",
      "id": 134949695,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2043764026/image_2043764026.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Fund returned -17.65%, reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended March 31, 2025.",
      "url": "https://finnhub.io/api/news?id=a63404a629040b3ee1dfbeb821589ec1ac714a5cd7b1b3f88d08123c42a9a6a6"
    }
  },
  {
    "ts": null,
    "headline": "COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?",
    "summary": "Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?",
    "url": "https://finnhub.io/api/news?id=0d7a884c01e39a9cdc171c618cfaaceb69d93db18b5d7c6ee17f3da69b4b4c5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748868180,
      "headline": "COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?",
      "id": 134952909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?",
      "url": "https://finnhub.io/api/news?id=0d7a884c01e39a9cdc171c618cfaaceb69d93db18b5d7c6ee17f3da69b4b4c5b"
    }
  },
  {
    "ts": null,
    "headline": "J&J: pasritamig shows promise in advanced prostate cancer",
    "summary": "Johnson & Johnson has announced positive initial Phase 1 results for pasritamig , a first-in-class bispecific antibody, in the treatment of metastatic castration-resistant prostate cancer . The...",
    "url": "https://finnhub.io/api/news?id=2ba92b0c79d15224a30893207297a3ef7156fe62ac908c6169a0710c1b5352db",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748858012,
      "headline": "J&J: pasritamig shows promise in advanced prostate cancer",
      "id": 134939054,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson has announced positive initial Phase 1 results for pasritamig , a first-in-class bispecific antibody, in the treatment of metastatic castration-resistant prostate cancer . The...",
      "url": "https://finnhub.io/api/news?id=2ba92b0c79d15224a30893207297a3ef7156fe62ac908c6169a0710c1b5352db"
    }
  },
  {
    "ts": null,
    "headline": "Dow falls 150 points on losses for 3M, Sherwin-Williams Co. stocks",
    "summary": "Dow falls 150 points on losses for 3M, Sherwin-Williams Co. stocks",
    "url": "https://finnhub.io/api/news?id=a6ac72fb0fb1448f94b45b5be90d2b4883893fa033ef1c058e9243d89a8a7d45",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748857500,
      "headline": "Dow falls 150 points on losses for 3M, Sherwin-Williams Co. stocks",
      "id": 134940365,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow falls 150 points on losses for 3M, Sherwin-Williams Co. stocks",
      "url": "https://finnhub.io/api/news?id=a6ac72fb0fb1448f94b45b5be90d2b4883893fa033ef1c058e9243d89a8a7d45"
    }
  },
  {
    "ts": null,
    "headline": "The HealthCare Sector: A Look At Sector Earnings Trends",
    "summary": "Healthcare has been a tough sector in 2025. It looks like Q2 could be the low point for healthcare earnings growth for this year, but the sector is being buffeted by a number of headwinds.",
    "url": "https://finnhub.io/api/news?id=151bad27b00f32c17934d7f5dd806d95493549b0b885eebb4ae421d7bed8eab7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748845800,
      "headline": "The HealthCare Sector: A Look At Sector Earnings Trends",
      "id": 134935856,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189796464/image_2189796464.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Healthcare has been a tough sector in 2025. It looks like Q2 could be the low point for healthcare earnings growth for this year, but the sector is being buffeted by a number of headwinds.",
      "url": "https://finnhub.io/api/news?id=151bad27b00f32c17934d7f5dd806d95493549b0b885eebb4ae421d7bed8eab7"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income Update: Q1 2025",
    "summary": "Dividend Income Update: Q1 2025",
    "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748843880,
      "headline": "Dividend Income Update: Q1 2025",
      "id": 134935601,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e"
    }
  }
]